The CV safety and benefits of GLP-1 RAs have been shown in multiple cardiovascular outcome trials (CVOTs) such as LEADER (liraglutide), SUSTAIN-6 (once-weekly injectable semaglutide), PIONEER-6 (oral semaglutide), and REWIND (dulaglutide) and most recently SOUL (oral semaglutide), with results that have positioned this class of antihyperglycemic drugs as first-line choices, in the absence of contraindications, in the treatment of patients with T2D and ASCVD or indicators of high CVD risk, independently of glucose control. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.